ArticleMolecular cancer research : MCR2020
PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Dynamic lysine acetylation and succinylation of platelet proteins regulates platelet storage lesion: mechanistic insights from multi-omics.Annals of medicine · 2026Article
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
- Metformin Impairs Breast Cancer Growth through the Inhibition of PRMT6.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Race and Sex Differences in PRMT6 Expression in Lung Tumors in Relation to Neighborhood Violence.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- The Role of Protein Arginine Methylation as a Post-Translational Modification in Cellular Homeostasis and Disease.Biology · 2025Review
- Therapeutic targeting of protein arginine methyltransferases reduces breast cancer progression by disrupting angiogenic pathways.Biochemistry and biophysics reports · 2025Review
- Assessment of PRMT6-dependent alternative splicing in pluripotent and differentiating NT2/D1 cells.Life science alliance · 2025Article
- Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations.Nature communications · 2024Article
- PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration.Cell death & disease · 2024Article
- Arginine methylation of ALKBH5 by PRMT6 promotes breast tumorigenesis via LDHA-mediated glycolysis.Frontiers of medicine · 2024Article
- Inhibition of protein arginine methyltransferase 6 activates interferon signaling and induces the apoptosis of endometrial cancer cells via histone modification.International journal of oncology · 2024Article
- Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men.iScience · 2024Article
- The Role of Protein Methyltransferases in Immunity.Molecules (Basel, Switzerland) · 2024Review
- Machine Learning for Digital Scoring of PRMT6 in Immunohistochemical Labeled Lung Cancer.Cancers · 2023Article
- Article
- Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation (Review).International journal of oncology · 2023Review
- Article
- Article
- PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism.Acta pharmaceutica Sinica. B · 2023Article
- Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy.Frontiers in immunology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 4 institutions in 2 countries.
Sreedevi AvasaralaMedicine/Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Pei-Ying WuMedicine/Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Samia Q KhanDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois.ORCID 0000-0001-9516-6852
Su YanlinMedicine/Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Michelle Van ScoykMedicine/Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Jianqiang BaoDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas.ORCID 0000-0003-1248-2687
Alessandra Di LorenzoDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas.
Odile DavidDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois.
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas.ORCID 0000-0002-8899-1050
Vineet GuptaDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois.
Robert A WinnMedicine/Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Rama Kamesh BikkavilliMedicine/Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois. kamesh@uic.edu.
University of Illinois Chicago · USRush University Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Science and Technology of China · CN
Funding
Research Education CoreU54CA202997 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PETERSON, CARYN E., PETERSON, CARYN E. · 2015 to 2024
$13.8MThe Chicago Cancer Health Equity Collaborative (ChicagoCHEC)U54CA202995 · NCI · NORTHEASTERN ILLINOIS UNIVERSITY · PI HIBDON, JOSEPH EDWARD · 2015 to 2024
$9.5MCancer Health Equity Career Development ProgramT32CA057699 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Marian L. Fitzgibbon · 2018 to 2026
$3.0MThe Functional Analysis of the Coactivator CARM1R01GM126421 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BEDFORD, MARK T. · 2018 to 2021
$1.4MRole of the noncanonical WNT pathway in non-small cell lung cancerR01CA138528 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WINN, ROBERT A. · 2010 to 2014
$1.4MThe Wnt and Prostacyclin pathways act in concert to inhibit NSCLC cell growthI01BX001004 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI WINN, ROBERT A. · 2011 to 2014
–BLRD VA I01 BX001004NCI NIH HHS R01 CA138528NCI NIH HHS T32 CA057699NCI NIH HHS U54 CA202995NCI NIH HHS U54 CA202997NIGMS NIH HHS R01 GM126421
Abstract
Increased expression of protein arginine methyl transferase 6 (PRMT6) correlates with worse prognosis in lung cancer cases. To interrogate the
Indexed as
AnimalsCell Culture TechniquesCell Line, TumorCell ProliferationDisease Models, AnimalDisease ProgressionHumansLung NeoplasmsMacrophagesMiceNuclear ProteinsProtein-Arginine N-MethyltransferasesSurvival AnalysisNuclear ProteinsPRMT6 protein, humanProtein-Arginine N-Methyltransferases
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.